OC
NVCT icon

Oppenheimer & Co’s Nuvectis Pharma NVCT Stock Holding History

Oppenheimer & Co’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$569K Hold
73,566
– – 0.01% 1138
2025
Q4 		$555K Buy
73,566
+4,500
+7% +$29.3K 0.01% 1035
2025
Q3 		$416K Hold
69,066
– – 0.01% 1250
2025
Q2 		$516K Buy
69,066
+28,066
+68% +$255K 0.01% 1135
2025
Q1 		$401K Buy
41,000
+16,000
+64% +$115K 0.01% 1154
2024
Q4 		$135K Buy
+25,000
New +$157K ﹤0.01% 1492

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Oppenheimer & Co's NVCT Position: Q1 2026 in Review

Oppenheimer & Co held its Nuvectis Pharma (NVCT) position steady in Q1 2026 at 73,566 shares worth $569K. The position accounts for 0.01% of the portfolio, ranked #1138.

Oppenheimer & Co first reported a position in NVCT in Q4 2024 and has held it in 6 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Oppenheimer & Co held 73,566 shares of Nuvectis Pharma worth $569K as of Q1 2026.
  • Oppenheimer & Co left its Nuvectis Pharma share count unchanged in Q1 2026.
  • Nuvectis Pharma made up 0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1138 holding.
  • Oppenheimer & Co first reported a position in Nuvectis Pharma in Q4 2024 and has held it in 6 quarters since.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.